MONTREAL, Aug. 1, 2018 /CNW/ - Optina Diagnostics, a leading-edge company with a vision to revolutionize the way that Alzheimer's is diagnosed, announces today a collaborative agreement with Imagia, a Healthcare AI company whose mission is to personalize health care. Together they will be focusing on the development of retinal biomarkers for Alzheimer's disease by leveraging spectral retinal images combined with deep learning architectures to predict patient outcomes and detect disease specific markers.
The solution towards a cure for Alzheimer's begins with the early detection of the disease in order to treat it before irreversible damage occurs. Currently, the diagnosis of Alzheimer's relies on a variety of neurobehavioral tests that are subjective, as well as PET scans that are both expensive and inconvenient.
"The opportunity to work closely with the experts at Imagia Cybernectics on the discovery of spectral biomarkers for early stage, low cost, non-invasive diagnostics of Alzheimer's disease is extremely motivating," said David Lapointe, CEO at Optina Diagnostics.
"By combining our data rich images from a large number of very narrowband wavelengths with the deep learning pipelines developed by Imagia Cybernetics, we believe we can accelerate the delivery of novel biomarkers and predict patient outcomes".
"This collaboration aligns with Imagia's initiative in preventative health. Leveraging our deep radiomics platform, we aim at discovering actionable imaging biomarkers from Optina's unique spectral retinal imaging, to improve Alzheimer's patient management." said Florent Chandelier CTO at Imagia.
About Optina Diagnostics
Optina Diagnostics is a Montreal based company focused on the development of technology for the early detection of disease through hyperspectral imaging of the eye. With a first application in the early diagnosis of Alzheimer's, Optina brings a radiomics approach to biomarker detection. optinadx.com
Imagia Cybernetics is a Healthcare AI company, translating technology innovations into impactful patient care and experience. Our team of AI experts and clinical practitioners have purpose-built Evidens, a collaboration ecosystem that powers discovery and clinical adoption at scale — federating patient data across institutions and uniting creative minds in AI & healthcare. Together with leading pharma, imaging and interventional medical device companies, we are propelling healthcare AI products to reveal the full picture of personalized healthcare. Imagia.com
SOURCE Optina Diagnostics
For further information: George Mallin, [email protected], 514-394-0797